Cyclodextrin Stabilization of Benzodiazepine ADC Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The removal of benzodiazepine drug-related impurities from mixtures comprising benzodiazepine antibody-drug conjugates (ADCs) is inefficient due to the high potency and nature of benzodiazepine drugs, leading to challenges in purification and stability.
Innovation Solution
The use of cyclodextrin during tangential flow filtration aids in the efficient clearance of benzodiazepine drug-related impurities by maintaining solubility and preventing aggregation, thereby improving the stability of benzodiazepine ADCs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional purification methods are used to remove benzodiazepine drug-related impurities, then the purification process is simple, but the removal efficiency is insufficient due to the high potency and nature of benzodiazepine drugs
Solution Approach 1:
Cyclodextrin is introduced as an intermediary substance that forms inclusion complexes with benzodiazepine drug-related impurities. The cyclodextrin molecule has a hydrophobic cavity that selectively binds to the hydrophobic benzodiazepine impurities, facilitating their removal from the ADC mixture through tangential flow filtration while leaving the ADC intact
Solution Approach 2:
The invention changes the solubility parameters of the impurities by forming cyclodextrin inclusion complexes. This complexation alters the physical-chemical properties of the benzodiazepine impurities, making them more amenable to separation by tangential flow filtration based on size and solubility differences
2Stability of the object's composition
If cyclodextrin is added to maintain solubility and prevent aggregation, then the stability of benzodiazepine ADCs is improved, but the formulation complexity increases
Solution Approach 1:
Cyclodextrin serves as a stabilizing intermediary that prevents aggregation of benzodiazepine ADCs by forming inclusion complexes with potential aggregating agents or by maintaining proper solubility. The cyclodextrin acts as a molecular shield that prevents unwanted interactions between ADC molecules
Solution Approach 2:
The addition of cyclodextrin changes the solubility and conformational parameters of the ADC formulation. It modifies the physical-chemical environment to favor monomeric ADC species and prevent aggregation, thereby improving stability without requiring complex formulation components
3Reliability
If tangential flow filtration is performed without cyclodextrin, then the process is simpler, but aggregation occurs and chemical degradation increases
Solution Approach 1:
Cyclodextrin is added to the ADC mixture before tangential flow filtration to preemptively prevent aggregation and chemical degradation. The cyclodextrin forms protective complexes with the ADC and impurities beforehand, ensuring stability during the filtration process and preventing degradation that would occur without this preliminary protective action
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Cyclodextrin enhances the removal of impurities, reduces aggregation, and stabilizes benzodiazepine ADCs, maintaining their chemical integrity and reducing chemical degradation, resulting in improved formulations for therapeutic use.
Implementation Method 1
cyclodextrin is used to aid in the purification process... maintaining solubility and preventing aggregation
Implementation Method 2
subjecting a mixture comprising benzodiazepine ADCs and benzodiazepine drug-related impurities to tangential flow filtration
Data Source
AI summary
Disclosed are formulations, including both liquid and lyophilized formulations, comprising a benzodiazepine antibody-drug conjugate (ADC) and a cyclodextrin. Also disclosed are methods of purifying mixtures comprising benzodiazepine antibody-drug conjugates and process drug-related impurities.